Ansbert Gadicke Sells 40,669 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ansbert Gadicke sold 40,669 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $1.09, for a total transaction of $44,329.21. Following the transaction, the insider directly owned 5,691,191 shares in the company, valued at approximately $6,203,398.19. This trade represents a 0.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Ansbert Gadicke also recently made the following trade(s):

• On Tuesday, November 11th, Ansbert Gadicke sold 55,810 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.14, for a total value of $63,623.40.
• On Monday, November 10th, Ansbert Gadicke sold 48,570 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.18, for a total value of $57,312.60.
• On Friday, November 7th, Ansbert Gadicke sold 68,480 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.11, for a total value of $76,012.80.
• On Thursday, November 6th, Ansbert Gadicke sold 54,452 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.21, for a total value of $65,886.92.
• On Wednesday, November 5th, Ansbert Gadicke sold 47,950 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.22, for a total value of $58,499.00.
• On Tuesday, November 4th, Ansbert Gadicke sold 140,488 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.22, for a total value of $171,395.36.
• On Monday, November 3rd, Ansbert Gadicke sold 94,063 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.29, for a total value of $121,341.27.
• On Friday, October 31st, Ansbert Gadicke sold 114,044 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.28, for a total value of $145,976.32.
• On Thursday, October 30th, Ansbert Gadicke sold 86,936 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.43, for a total transaction of $124,318.48.
• On Wednesday, October 29th, Ansbert Gadicke sold 134,240 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.55, for a total transaction of $208,072.00.

Werewolf Therapeutics Trading Down 14.9%

NASDAQ HOWL opened at $0.93 on Friday. Werewolf Therapeutics, Inc. has a one year low of $0.60 and a one year high of $2.38. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87. The company has a market capitalization of $45.03 million, a price-to-earnings ratio of -0.57 and a beta of 0.72. The company’s 50-day simple moving average is $1.58 and its two-hundred day simple moving average is $1.33.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03. Equities analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HOWL has been the topic of several recent research reports. Bank of America dropped their target price on Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, August 25th. JMP Securities decreased their price objective on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research note on Thursday, August 21st. Zacks Research raised Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 16th. Citigroup reiterated a “market outperform” rating on shares of Werewolf Therapeutics in a research note on Wednesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

Institutional Trading of Werewolf Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in HOWL. Jane Street Group LLC acquired a new stake in Werewolf Therapeutics in the second quarter worth about $409,000. Vanguard Group Inc. increased its holdings in shares of Werewolf Therapeutics by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after acquiring an additional 109,796 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Werewolf Therapeutics during the second quarter valued at about $113,000. Y Intercept Hong Kong Ltd purchased a new position in shares of Werewolf Therapeutics in the 2nd quarter valued at approximately $92,000. Finally, AQR Capital Management LLC acquired a new stake in Werewolf Therapeutics in the 1st quarter worth approximately $79,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.